DUBLIN–(BUSINESS WIRE)–The “Bladder Cancer: Opportunity Analysis and Forecasts to 2028” report has been added to ResearchAndMarkets.com’s offering.
Summary:
The Bladder Cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM – US, France, Germany, Italy, Spain, UK, and Japan) at a compound annual growth rate (CAGR) of 18.5%. The exponential growth of the bladder cancer market will be driven by an increasing incident patient population and the approval and launch of new branded therapies with different MOAs: Balversa, Padcev, Vofatamab, Vicinium, Qapzola, N-803 and Instilidrin.
In addition, the label expansion of currently marketed therapies: PD-1/PD-L1 checkpoint inhibitors in combination with chemotherapies or other immuno-oncology agents will promote market growth during the forecast period. PD-1/PD-L1 checkpoint inhibitors are highly anticipated in bladder cancer and they are expected to have greater adoption and usage in different lines of therapy across the 7MM (US, France, Germany, Italy, Spain, UK, and Japan), especially in the areas where unmet need is the highest.
However, a major barrier for market growth in bladder cancer will be identifying the patient population with specific mutations for targeted therapy regimens, which is not feasible for all patients as costs for identification would be expensive for the payers, and will limit the usage of these drugs. In the EU and Japan, the usage of checkpoint inhibitors other than Keytruda and Tecentriq is currently difficult due to reimbursement restrictions. Competition from other drugs and reimbursement restriction will tamper the growth of the market significantly.
Among the pipeline candidates, PD-1/PD-L1 inhibitors as monotherapy or as a combination regimen are expected to result in significant revenues due to premium pricing and clinical benefit in BCG-relapsed and refractory patients, as well as in platinum based chemotherapy ineligible patients.
The usage of PD-1/PD-L1 inhibitors in bladder cancer is expanding, translating to the major contributor of increased revenue in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) over the forecast period. Label expansion of PD-1/PD-L1 inhibitors and the launch of novel drugs such as Vicinium, N-803, Instiladrin for non-muscle invasive bladder cancer population are major drivers of the US market.
Key opinion leaders (KOLs) across the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) are very enthusiastic about Padcev and sales revenues for this drug is set to increase at a CAGR of 18.8% from the time of launch in 2020 over the forecast period. In addition, evaluating targeted therapy regimens in combination with immune checkpoint inhibitors will aid in better product adoption across all type of bladder cancer patients.
The latest report Bladder Cancer: Opportunity Analysis and Forecasts to 2028, provides an overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. The report further brings in annualized bladder cancer therapeutics market revenue, strategic competitor assessment, clinical trial mapping, pipeline drug analysis and analysis of the current and future market competition in the global bladder cancer market.
Key Questions Answered by the report:
- How will the earlier use of immune checkpoint inhibitors and targeted therapies agent in NMIBC, MIBC, and locally advanced and metastatic settings affect the bladder cancer treatment algorithm?
- The bladder cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfill them?
- Eight late-stage pipeline agents are going to enter the bladder cancer market from 2018 onwards. Will the late-stage drugs make a significant impact on the bladder cancer market? Which of these drugs will have the highest peak sales, and why?
Scope:
- Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bladder cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global bladder cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Bladder Cancer: Executive Summary
2.1 Bladder Cancer Market in the 7MM Is Expected to Grow Exponentially in Size from 2018 to 2028
2.2 Big Pharma Focuses on Label Expansion, While Smaller Companies Focus on Developing Drugs with Novel Mechanisms of Action
2.3 The Level of Unmet Need Will Still Remain Across Bladder Cancer Setting With the Opportunity for New Drug Entrants to Address Needs
2.4 Introduction of Novel Drug Along With Greater Adoption among PD-1/PD-L1 Checkpoint Inhibitor Drugs in Advanced-Stage Disease Setting
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Bladder Cancer (2018-2028)
5.6 Discussion
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Additional Therapeutic Modalities across the Disease Spectrum
7.3 Evaluation of Novel MOAs for Advanced Disease Stage
7.4 Improved Drugs in NMIBC Patients with Tumor Recurrence/BCG Recurrence and Refractory
7.5 Improved Diagnostic and Drug Delivery Methods for Later Disease Stages
8 R&D Strategies
8.1 Overview
8.1.1 Orphan and Regulatory Designations Accelerate Drug Development in Bladder Cancer
8.1.2 Involvement of Both Big and Small Biotech Companies in Drug Development
8.1.3 Novel Immunotherapy Combinations and Label Expansions
8.2 Clinical Trials Design
8.2.1 Registrational Studies: Open-Label, Non-comparative Trial Designs Still Prevalent
8.2.2 Variability of Trial Endpoints in Both the NMIBC and Advanced Disease Settings
9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Commercial Benchmark of Key Pipeline Drugs
10.2 Competitive Assessment
10.3 Top-Line 10-Year Forecast
10.3.1 US
10.3.2 5EU
10.3.3 Japan
11 Appendix
Companies Mentioned
- AstraZeneca
- Astellas Pharma/ Seattle Genetics
- Bristol-Myers Squibb
- Ferring Pharmaceuticals
- Immunity Bio
- Janssen/J&J
- Merck & Co.
- Merck KGaA/ Pfizer
- Rainier Therapeutics
- Roche (Genentech)
- Sesen Bio
- Spectrum Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/fut0k8
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900